Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: synchro who wrote (300)	1/29/1999 9:46:00 PM
From: Dr Smith	Respond to of 656

Sybchro - Be careful for what you ask for! The very last thing we need in here is the internet people, and all the daytraders the follow. They would run the stock price up to $1000, and the rest of us would be so confused that we would not know if it was time to sell till it was to late. Incidently, I am long genz, bgen, imnx, agmn, chir, gild, cnto, and a few others. I don't recall the 1992 crash in biotech's because all of my stocks are up, except chiron which has been a bit of a sleeper, but it is still in the run. Incidently, if you insist on investing in the internet, you may want to look at aims. It is undervalued, IMHO, for the only reason that it is traded on the BB.

To: synchro who wrote (300)	2/3/1999 9:38:00 PM
From: Buckeye	Read Replies (1) \| Respond to of 656

Ouch . . . you raised some great points but today shows why the biotechs have never been able to put together a monster since AMGN in 1991 (and what a monster that was) . . . like it or not the momentum funds rule when you get outside the normal valuation parameters and to keep them in the game you must have estimates that go up, something that biotech hasn't seen since that marvelous run in 1991 . . . i guess with IMNX i was hoping to relive the AMGN glory days but it's not to be (at least not this qtr.) . . . it just kills me that biotech cos. have such a difficult time blowing out the #'s, the comment "Enbrel sales are off the charts" is followed by "due to increased spending on the rollout" . . . maybe the analysts always get too hyped and set their ests. too high, or mgmts. overhype new products to the analysts leading to overoptimistic projections . . . whatever it is one day there will be a biotech co. with a terrific product and the common sense to "talk the street down" a la Bill Gates so that i can relive 1991 one more time